Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Original 1998 Curran EORTC Mesothelioma Prognostic Index

A five-factor weighted baseline prognostic index for malignant pleural mesothelioma.

Evidence-based context for fast calculator use

Purpose:
Reproduce the original EORTC weighted score and historical prognostic grouping.
Population:
Adults with malignant pleural mesothelioma in historical EORTC phase-II chemotherapy cohorts.
Factors:
WBC >8.3 x 10^9/L, ECOG 1-2, Probable or possible diagnosis, Sarcomatous histology, Male sex
Reference:
Curran et al. J Clin Oncol. 1998;16(1):145-152.
HomeMesothelioma EORTC Prognostic Index
Pin your most used calculators here by clicking the star in the dropdown.

Mesothelioma EORTC Prognostic Index

x 10^9/L

Clinical Context & Background

This calculator reproduces the original 1998 Curran EORTC prognostic index for malignant pleural mesothelioma. The weighted score uses baseline white blood cell count, ECOG performance status, diagnostic certainty, sarcomatous histology, and sex. The exact weighted score, not a count of adverse factors, determines the original good- or poor-prognosis group.
The model was developed from adults enrolled in historical EORTC phase-II chemotherapy studies. Its one-year survival values are cohort observations, not individualized survival estimates. It is not a screening, diagnostic, postoperative, treatment-selection, or medical-decision tool.
Primary Source EvidenceCurran D, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-152. doi:10.1200/JCO.1998.16.1.145.
Formula Logic
Original 1998 EORTC EPS = 0.55 x (WBC >8.3) + 0.60 x (ECOG 1-2) + 0.52 x (probable/possible diagnosis) + 0.67 x (sarcomatous histology) + 0.60 x (male).

Reference Data

Raw weighted EPSOriginal groupHistorical 1-year survival
<=1.27Good prognosis40%
>1.27Poor prognosis12%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use pretreatment baseline information for an adult with established malignant pleural mesothelioma resembling the original EORTC phase-II cohorts.
  • Enter the unrounded WBC and clinician-assessed ECOG, histology, diagnosis certainty, and sex categories.

How To Interpret

  • Raw weighted EPS <=1.27 is the original good-prognosis group; EPS >1.27 is the poor-prognosis group.
  • WBC exactly 8.3 x 10^9/L is not adverse. Biphasic or other non-sarcomatous histology does not receive the sarcomatous coefficient.

What To Do Next

  • Interpret the historical group with current staging, pathology, molecular findings, comorbidity, treatment options, patient goals, and specialist assessment.
  • Do not choose treatment or supportive care from this score alone.

Limitations

  • Historical EORTC phase-II cohorts and treatments may not represent contemporary outcomes.
  • Not for screening, diagnosis, postoperative reassessment, surveillance, or treatment selection.
  • The historical one-year survival values are not individualized survival probabilities.

Validated Population

Baseline adults with malignant pleural mesothelioma in the original EORTC phase-II chemotherapy cohorts.

Exact threshold example

Sarcomatous histology (0.67) plus male sex (0.60) gives EPS 1.27 and remains in the original good-prognosis group.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed EORTC cases passed through visible production controls at weighted scores 0.00, exact cutoff 1.27, and 1.82.
    • No unexpected N/A, literal undefined value, stale control, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/eortc-mesothelioma-prognostic-score-2026-08-03.json.

  2. : Local browser remediation verified; production retest pending

    • Corrected the result trace method identifier from the unsupported `formula` value to the registered `equation` renderer method; the Curran weighted EPS and cutoff were unchanged.
    • Ten local visible-browser cases passed, including WBC equality and just-above behavior, every weighted branch, EPS 1.27, an all-adverse poor-prognosis case, required-field feedback, and reset/repeat behavior.
    • The original production crash finding remains open until deployment and a fresh public-browser run.

    Local diagnostic evidence is retained in validation/browser-production/eortc-mesothelioma-prognostic-score.local-remediation.json.

  3. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 1/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-calculation-ui-and-console. critical: Every valid tested EORTC submission replaced the calculator with the browser error surface `This page couldn’t load`; no weighted EPS, prognostic group, historical cohort outcome, trace, or result card survived. | medium: Production also emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/eortc-mesothelioma-prognostic-score.json.

  4. : Browser input adapter corrected and reverified

    • Accepted finite number values already normalized by the shared calculator form while retaining strict malformed-input rejection.
    • No equation, cutoff, unit, classification, or applicability rule changed; calculator-specific verification and the calculator-wide browser-input audit passed.

  5. : Full validation test

    • 384/384 independent weighted-model, exact-boundary, invalid-input, trace, outcome, wording, UI/integration, and immutability checks passed.
    • No registered master panel calculates this EORTC index; no panel receives inherited verification.

  6. : Calculation and input-contract correction

    • Replaced adverse-factor counting with Curran's exact weighted EPS coefficients and preserved the raw EPS <=1.27 versus >1.27 boundary.
    • Separated sarcomatous histology from biphasic/other disease, removed favorable defaults and pre-scored inputs, and added strict raw-value validation plus historical prognostic-only wording.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Small Cell Lung Cancer Staging (VALSG)Solitary Pulmonary Nodule Malignancy Risk (Mayo)Herder Model (Pulmonary Nodule)

Frequently Asked Questions

Does WBC exactly 8.3 x 10^9/L add 0.55?

No. The original adverse criterion is strictly greater than 8.3.

Does biphasic histology receive the sarcomatous coefficient?

No. Only sarcomatous histology receives the 0.67 coefficient in the locked original model.

Is EPS exactly 1.27 poor prognosis?

No. Exactly 1.27 remains in the original good-prognosis group; only values above 1.27 enter the poor-prognosis group.

Evidence-based oncology decision support. Verify with clinical guidelines.